Pipeline

We are advancing a diverse pipeline of inhaled therapies for the treatment of severe respiratory diseases.

Our lead product candidate is inhaled imatinib (AER-901) for the treatment of pulmonary arterial hypertension (PAH).

501

INHALED HUMAN INSULIN

Available for partnership and out-license

601

INHALED SHORT ACTING GLUCAGON
LIKE PEPTIDE (GLP-1) ANALOG

Available for partnership and out-license

901

INHALED IMATINIB

  1. Dance BioPharm. “Multi-Site Investigation of Dance 501 Dosage Form Drop Dispenser- Actuations to Priming, Drop Accuracy and Repeatability.” 20 November 2014.
  2. International Diabetes Federation. DF Diabetes Atlas- 8th Edition. https://diabetesatlas.org/. Accessed July 24, 2019.
  3. Ikeda, H., Uzui, H., Morishita, T., et al. (2015). Effect of postprandial hyperglycemia on coronary flow reserve in patients with impaired glucose tolerance and type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 12(6), 405–410. doi: 10.1177/1479164115597866
  4. Akturk, H. K., Rewers, A., Joseph, H., et al. (2018). Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. Diabetes Technology & Therapeutics, 20(S2). doi: 10.1089/dia.2018.0114